Page 102 - Drug Class Review

Drug Effectiveness Review Project

rivastigmine (high) 73.8 68 97% 3% 0% 0% 38.4 19.62 Page 81 of 205

Groups similar at baseline: No (more females in high dose RIV group)

rivastigmine (low) 74.9 57 95% 4% 0% 1% 39.3 19.5 Timing of assessments: Baseline and weeks 12, 18, 26 or early termination PDS: high-dose RIV vs. placebo difference was significant (P < 0.05); only the high dose RIV group had a significantly greater number of treatment responders than placebo on the PDS (P < ADAS-Cog, CIBIC-plus: for both doses of RIV, the mean changes from baseline on ADAS-Cog and CIBIC-plus were significantly better than those for placebo (P < 0.05) MMSE: both high dose and low dose RIV MMSE scores were better than placebo, but only

Alzheimer classification: Mild-moderate

Health Outcome Measures: 0.01)

placebo 74.8 58 94% 4% 1% < 1% 40.4 20 Primary Outcome Measures: ADAS-Cog; CIBIC-plus; PDS Secondary Outcome Measures: MMSE; GDS Intermediate Outcome Measures: dose RIV was statistically significant (P < 0.05)

• • • •

Final Report Update 1 Authors: Corey-Bloom et al. Year: 1998 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Ethnicity: White • Black • Asian • Other • Other germane population qualities: Mean dementia duration • (months) Mean MMSE score • OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs